3 documents found, page 1 of 1
Osimertinib: A Game-Changer in Stage IV EGFR-Driven Lung Cancer
Silva, Sofia; Duarte, Joana; Simão, Carla; Felizardo, MargaridaLung cancer has a high mortality rate; however, treatment with tyrosine kinase inhibitors targeting specific molecular alterations has significantly improved the survival of patients with advanced or metastatic non-small cell lung carcinoma (NSCLC). EGFR mutations are present in approximately 15% of NSCLC cases. Osimertinib was approved in Portugal by Infarmed (Portuguese Medicines Agency) in 2021 as a first-li...
Um caso de Carcinoma do Pulmão de Não Pequenas Células EGFR
Campos, Sofia; Custódio, Catarina; Felizardo, Margarida; Calha, Jaime; Madureira, Rosa Maria; Teixeira, José AlbertoBackground: EGFR mutation is the most frequent in Non-Small Cell Lung Cancer and occurs mainly in women and non-smoking patients. Clinical case: We present the case of a 51-year-old female, former light smoker, diagnosed with lung adenocarcinoma in 2014, in stage IB. She underwent surgery and adjuvant therapy. She recurred after two years with metas-tatic lung and bone disease, with EGFR exon 21 mutation. Thera...
Detection and quantification of EGFR T790M mutation in liquid biopsies by dropl...
Silveira, Catarina; Sousa, Ana Carla; Janeiro, André; Malveiro, Sara; Teixeira, Encarnação; Brysch, Eva; Pantarotto, Marcos; Felizardo, MargaridaBackground: Liquid biopsy allows the identification of targetable cancer mutations in a minimally invasive manner. In patients with advanced non-small cell lung cancer (NSCLC), droplet digital PCR (ddPCR) is increasingly used to genotype the epidermal growth factor receptor (EGFR) gene in circulating cell-free DNA (cfDNA). However, the sensitivity of this method is still under debate. The aim of this study was ...